|
For Immediate Release, December 17, 2001 Integrative Proteomics Appoints Molly B. Schmid, Ph.D., Senior Vice President of Antibacterial Pharmaceuticals and Alliances TORONTO, ONTARIO (December 17, 2001) – Integrative
Proteomics, Inc.™ (IPI), a leader in structure based drug discovery,
today announced the appointment of Dr. Molly B. Schmid as Senior Vice
President, Antibacterial Pharmaceuticals and Alliances. Dr. John D. Mendlein, Chairman and CEO, said “Dr. Schmid’s previous industry experience, along with her pioneering work on using genetic and genomic methods for antimicrobial drug discovery, make her an ideal leader for IPI’s ongoing antibacterial program. Molly’s world class understanding of bacterial targets and drug discovery is a tremendous complement to IPI’s structure guided drug discovery paradigms.” Prior to joining Microcide, Dr. Schmid was Assistant Professor of Molecular Biology at Princeton University, where her research program led to the discovery of bacterial Topoisomerase IV and a genetic strategy for identifying new antimicrobial targets. Dr. Schmid received her B.S. in biology from State University of New York at Albany, her Ph.D. in biology from the University of Utah, and was a Research Fellow at the University of Oregon. Dr. Schmid is a co-inventor on numerous patents and pending patent applications in the field of antimicrobial drug discovery. She is a Fellow of the American Academy of Microbiology, a Searle/Chicago Community Trust Scholar and a Damon Runyon-Walter Winchell Fellow. IPI was founded in August, 2000 by Drs. Aled Edwards, Cheryl Arrowsmith and Jack Greenblatt, and has raised US $33 million since its inception. The Company’s proprietary Pharmaceutical Proteomics™ platform features mass spectrometry, NMR (nuclear magnetic resonance) spectroscopy and X-ray crystallography technologies from Bruker Daltonics (Nasdaq: BDAL), Bruker BioSpin and Bruker AXS (Nasdaq: BAXS), respectively. The Company’s processes enable high throughput target production and the determination of target function and structure to enhance target selection and accelerate chemistry. The Company’s Pharmaceutical Proteomics™ Platform also integrates the premier discovery capabilities of Aurora Biosciences to enhance IPI’s internal drug discovery efforts. The Company’s investors include the Lombard Odier Immunology Fund, Genesys Capital Partners Inc., and HBM BioVentures (Henri B. Meier, Chairman), as well as industrial partners Aurora Biosciences and the Bruker Companies. For more information, please contact: Integrative
Proteomics, Inc. Contact:
Dr. Joanne E. Harack |